Navigation Links
United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
Date:9/8/2009

SAN DIEGO, Sept. 8 /PRNewswire/ -- http://www.stemedica.com/ Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell research and manufacturing, has filed a patent application with the United States Patent and Trademark Office ("USPTO") for a proprietary methodology in the treatment for Diabetic Retinopathy. The patent application was published by the USPTO on August 27th of this year. The application is supported by extensive data and results from patients treated within a Clinical Study conducted outside of the United States beginning in January of 2006.

"Our patent application describes a dynamic method for treating diabetic retinopathy and other degenerative conditions of the eye," said Nikolai Tankovich, MD, PhD, Stemedica's President and Chief Medical Officer. "The breakthrough results from this study provide new hope for the thousands of patients suffering from the debilitating disease of Diabetic Retinopathy."

Stemedica's invention relates to the use of multiple stem cells and a transplantation methodology in the treatment of Diabetic Retinopathy. Participating patients had varying degrees of Diabetic Retinopathy and Diabetic Optic Neuropathy. Patients received neural progenitor cells by retrobulbar injection and mesenchymal stem cells administered intravenously. Patients were observed at baseline and then after treatment at days 2, 8, 14, 30, 60, 90, and 120. Annual physical and ophthalmic examinations were conducted each year thereafter for a three year period.

Noticeable patient findings included: overall visual function improvements by all eight patients within sixty (60) days of treatment; reduction in absolute scotomas; increases in the thickness of the optic nerve fiber; resorption of hemorrhages; no new micro bleeding edema of the nerve fiber layer; and, a decrease in macular edema. Improvement in the function of different layers of the retina and optic nerve were experienced as well as a reduction in the number of scotomas in the field of vision. None of the patients developed tumors, had impaired vision or experienced adverse health effects connected with the cell injections, and seven of the eight participating patients have maintained the overall vision improvements they gained from treatment three years later.

Diabetic retinopathy is damage to the eye's retina that occurs with long-term diabetes. It is a leading cause of adult blindness in the United States.

This patent application, Publication Number US2009/0214485 A1, is available for review via the USPTO at www.uspto.gov.

About Stemedica Cell Technologies, Inc. Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials. The company is currently developing regulatory pathways for stroke and wound repair. Stemedica is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc. contact Dave McGuigan at dmcguigan@stemedica.com.


'/>"/>
SOURCE Stemedica Cell Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
2. Premier Research Expands its Medical Device Operations to the United States
3. American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule
4. A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
5. Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. United States, Canada and Mexico Agree to Mutual Assistance During Public Health Emergencies
8. R-CALF United Stockgrowers of America: Fighting for the U.S. Cattle Producer
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
(Date:8/7/2017)... Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... quarter ended June 30, 2017.  All comparisons, unless otherwise noted, ... Second Quarter 2017 Highlights include: ... $1,089 million, an increase of 3.5% Total ... Gross margin of 7.5% versus 7.6% ...
Breaking Medicine Technology:
(Date:8/24/2017)... Raton (PRWEB) , ... August 24, 2017 , ... ... dietary supplements that help people improve all aspects of their health and wellness, ... States. , The step represents a component of Natural Subsistence’s aggressive marketing strategy ...
(Date:8/24/2017)... ... August 24, 2017 , ... Indosoft Inc. announces the ... of contact center application development experience. It represents a complete redesign of ... Indosoft designed Q-Suite NG for simple integration. A full set of APIs allows ...
(Date:8/23/2017)... ... 23, 2017 , ... Jachimowicz Law Group is excited to announce ... 115. The office is located between Schiele and Pershing avenues, with convenient parking for ... can still call the office at 408-246-5500. , Jachimowicz Law Group has ...
(Date:8/23/2017)... ... August 23, 2017 , ... Earlier this month, the Workgroup for Electronic ... IT to create efficiencies in healthcare information exchange and a trusted advisor to the ... which featured keynote addresses by Donald W. Rucker, MD, head of the Office ...
(Date:8/23/2017)... ... 2017 , ... Nightingale College continues the semiannual Give Back Day tradition for ... College dedicates to serving and volunteering for organizations that provide indispensable resources to the ... that need a little extra help. , The College’s Give Back Day initiative ...
Breaking Medicine News(10 mins):